Oncolytic Virus Cancer Therapy Market

Oncolytic virus cancer therapy sales will grow through 2036, led by solid tumor indications at a 31.2% share, supported by an expanding clinical trial pipeline for melanoma and glioblastoma. Herpes simplex virus holds a 22.5% share. The market is set to reach USD 44.8 million by 2026-end and USD 314.3 million by 2036.